Advertisement

Pharmaceutisch Weekblad

, Volume 12, Issue 2, pp 46–50 | Cite as

Helicobacter pylori in gastroduodenal disease

  • R. J. L. F. Loffeld
Review Articles

Abstract

Helicobacter pylori is a recently described Gram-negative micro-organism, which plays an important role in the pathogenesis of peptic ulcer disease and gastritis. In this paper an outline is given of the history and the pathophysiology ofHelicobacter pylori, as well as the therapeutic studies aimed at eradication of the bacterium in various clinical entities.

Keywords

Helicobacter pylori Duodenal ulcer Dyspepsia Gastritis Peptic ulcer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bizzozero G. Über die schlauchformigen Drusen des Magendarmkanals un die Beziehung ihres Epithels zu dem Oberflachen Epithel der Sleimhaut. Arch F Mikro Anayo 1893;42:82.Google Scholar
  2. 2.
    Krienitz W. Über das Auftreten von Mageninhalt bei Carcinoma ventriculi. Dtsch Med Wochenschr 1906;22:872.Google Scholar
  3. 3.
    Rosenow EC, Sandford AH. The bacteriology of ulcer of the stomach and duodenum in man. J Infect Dis 1915;17:219–26.Google Scholar
  4. 4.
    Doenges JL. Spirochetes in the gastric glands of Macacus rhesus and man without related disease. Arch Pathol 1939;27:469–77.Google Scholar
  5. 5.
    Freedburg AS, Barron LE. The presence of spirochetes in human gastric mucosa. Am J Dig Dis 1940;7:443–5.Google Scholar
  6. 6.
    Steer HW, Collin-Jones DG. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. Gut 1975;16:590–7.PubMedGoogle Scholar
  7. 7.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Anonymous.Campylobacter pylori becomesHeliobacter pylori. Lancet 1989;2:1019–20.Google Scholar
  9. 9.
    Marshall BJ, Royce H, Anneer DI, et al. Original isolation ofCampylobacter pyloridis from human gastric mucosa. Microbios Lett 1984;25:83–8.Google Scholar
  10. 10.
    Loffeld RJFL, Potters HVPJ, Arends JW, Stobberingh E, Flendrig JA, Van Spreeuwel JP.Campylobacter associated gastritis in patients with non-ulcer dyspepsia. J Clin Pathol 1988;41:84–8.Google Scholar
  11. 11.
    Potters HVPJ, Loffeld RJLF, Stobberingh E, Van Spreeuwel JP, Arends JW. Rapid staining ofCampylobacter pyloridis. Histopathology 1987;11:1223.Google Scholar
  12. 12.
    Montgomery EA, Martin DF, Peura DA. Rapid diagnosis ofCampylobacter pylori by Gram's stain. Am J Clin Pathol 1988;90:606–9.PubMedGoogle Scholar
  13. 13.
    Walters LL, Budin RE, Paull G. Acridine orange to identifyCampylobacter pyloridis in formalin fixed paraffin-embedded gastric biopsies. Lancet 1986;1:42.CrossRefGoogle Scholar
  14. 14.
    Kaldor J, Tee W, McCarthy P, Watson J, Dwyer B. Immune respons toCampylobacter pyloridis in patients with peptic ulceration. Lancet 1985;1:921.CrossRefGoogle Scholar
  15. 15.
    Von Wulffen H, Heesemann J, Buetzow GH, Loening T, Laufs R. Detection ofCampylobacter pyloridis in patients with antrum gastritis and peptic ulcers by culture, complement fixation test, and immunoblot. J Clin Microbiol 1986;24:716–20.PubMedGoogle Scholar
  16. 16.
    Loffeld RJLF, Stobberingh E, Flendrig JA, Van Spreeuwel JP, Arends JW. Diagnostic value of an immunoassay to detect antiCampylobacter pylori anti-bodies in non-ulcer dyspepsia. Lancet 1989;1:1182–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Marshall BJ, McGechie DB, Rogers PA, Glancy RJ.Pyloric Campylobacter infection in gastroduodenal disease. Med J Aust 1985;142:439–44.PubMedGoogle Scholar
  18. 18.
    McNulty CAM, Dent J, Wise R. Susceptibility of clinical isolates ofCampylobacter pyloridis to 11 anti-microbial agents. Antimicrob Agents Chemother 1985;28:837–8.PubMedGoogle Scholar
  19. 19.
    McNulty CAM, Gearty JC, Crump B, et al.Campylobacter pyloridis and associated gastritis: investigator blind placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 1986;293:645–9.Google Scholar
  20. 20.
    Mertens JCC, Dekker W, Ligtvoet EEJ, Blok P. Treatment failure of norfloxacin againstCampylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrob Agents Chemother 1989;33:256–7.PubMedGoogle Scholar
  21. 21.
    Jones DM, Lessels AM, Eldridge J.Campylobacter-like organisms on the gastric mucosa: culture, histological and serological studies. J Clin Pathol 1984;37:1002–6.PubMedGoogle Scholar
  22. 22.
    Buck GE, Gourley WK, Lee WK, Subramanyam K, Latimer JM, DiNuzzo AR. The relation ofCampylobacter pyloridis to gastric and peptic ulcer. J Infect Dis 1986;153:664–9.PubMedGoogle Scholar
  23. 23.
    Marshall BJ, Armstrong JA, McGechie DB, Glancy J. Attempts to fulfill Koch's postulates for pyloricCampylobacter. Med J Aust 1985;142:436–9.PubMedGoogle Scholar
  24. 24.
    Morris A, Nicholson G. Ingestion ofCampylobacter pyloridis causes gastritis and raised fasting pH. Am J Gastroenterol 1987;82:192–9.PubMedGoogle Scholar
  25. 25.
    Goodwin CS, McCulloch RK, Armstrong JA, Wee SH. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (Campylobacter pyloridis) from the human gastric mucosa. J Med Microbiol 1985;19:257–67.PubMedGoogle Scholar
  26. 26.
    Hazell SL, Lee A.Campylobacter pyloridis, urease, hydrogen ion back diffusion and gastric ulcers. Lancet 1986;2:15–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Slomiany BL, Bilski J, Munty UL, et al.Campylobacter pyloridis degrades mucin and undermines gastric mucosal integrity. Gastroenterology 1987;92:1645.Google Scholar
  28. 28.
    Leunk RD, Johnson PT, David BL, Kraft WG, Morgan DR. Identification off cytotoxic activity produced byCampylobacter pyloridis. In:Campylobacter IV. Proceedings of the 4th International Workshop onCampylobacter Infections. Kopenhagen (in press).Google Scholar
  29. 29.
    Baskerville A, Newell DG. Natural occurring chronic gastritis andCampylobacter pylori infection in the rhesus monkey: a potential model for gastritis in man. Gut 1988;29:465–72.PubMedGoogle Scholar
  30. 30.
    Jones DM, Curry A. Ultrastructural study of gastricCampylobacter-like organisms (GCLO) from man, baboon, pig, and ferret. In:Campylobacter IV. Proceedings of the 4th International Workshop onCampylobacter Infections. Kopenhagen (in press).Google Scholar
  31. 31.
    Talley NJ, Piper DW. The association between nonulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 1985;20:896–900.PubMedGoogle Scholar
  32. 32.
    Heatley RV, Rathbone BJ. Dyspepsia: a dilemma for doctors? Lancet 1987;1:779–81.CrossRefGoogle Scholar
  33. 33.
    Jones DM, Lessels AM, Eldridge J.Campylobacter-like organisms on gastric mucosa: culture, histological, and serological studies. J Clin Pathol 1984;37:1002–6.PubMedGoogle Scholar
  34. 34.
    Barthel JS, Westblom TW, Heavy AD, Gonsalez F, Everet ED. Gastritis andCampylobacter pylori in healthy asymptomatic volunteers. Arch Intern Med 1988;148:1149–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Rokkas T, Pursey C, Uzoechina E, et al. Non-ulcer dyspepsia and short term De Nol therapy: a placebo controlled trial with particular reference to the roleCampylobacter pylori. Gut 1988;29:1386–91.PubMedGoogle Scholar
  36. 36.
    Loffeld RJLF, Potters HVPJ, Stobberingh E, Van Spreeuwel JP, Flendrig JA, Arends JW.Campylobacter associated gastrits in patients with non-ulcer dyspepsia: a placebo controlled double blind trial with colloidal bismuth subcitrate. Gut 1989;30:1206–12.PubMedGoogle Scholar
  37. 37.
    Glupczynski Y, Burette A, Labbe M, Deprez C, Reuck M, Deltenre M.Campylobacter pylori associated gastritis: a double blind placebo controlled trial with amoxycillin. Am J Gastroenterol 1988;83:365–72.PubMedGoogle Scholar
  38. 38.
    Humphreys H, Bourke S, Dooley C, et al. Effect of treatment onCampylobacter pylori in peptic disease: a randomised prospective trial. Gut 1988;29:279–83.PubMedGoogle Scholar
  39. 39.
    Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated withCampylobacter pylori. Gastroenterology 1988;95:1178–84.PubMedGoogle Scholar
  40. 40.
    Oderda G, Holton J, Altare F, Vaira D, Ainley C, Ansaldi N. Amoxycillin plus tinidazole forCampylobacter pylori gastritis in children: assessment by serum IgG antibody, pepsinogen I and gastrin. Lancet 1989;1:690–2.CrossRefPubMedGoogle Scholar
  41. 41.
    Goodwin CS. Duodenal ulcer,Campylobacter pylori, and the “leaking roof” concept. Lancet 1988;2:1467–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Lane MR, Lee SP. Recurrence of duodenal ulcer after medical treatment. Lancet 1988;1:1147–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer. Drugs 1976;12:401–11.PubMedGoogle Scholar
  44. 44.
    Coghlan JG, Humphreys H, Dooley C, et al.Campylobacter pylori and recurrence of duodenal ulcer a 12-month follow-up study. Lancet 1987;1:1109–11.CrossRefGoogle Scholar
  45. 45.
    Marshall BJ, Warren JR, Blincow ED, et al. Prospective double blind trial of duodenal ulcer relapse after eradication ofCampylobacter pylori. Lancet 1988;2:1437–42.CrossRefPubMedGoogle Scholar
  46. 46.
    Zheng ZT, Wong ZY, Chu YX, et al. Double-blind short-term trial of furazolidone in peptic ulcer. Lancet 1985;1:1048–9.Google Scholar
  47. 47.
    Hui WM, Lam SK, Chau PY, et al. Persistence ofCampylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci 1987;32:1255–60.CrossRefPubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1990

Authors and Affiliations

  • R. J. L. F. Loffeld
    • 1
  1. 1.Department of Internal MedicineUniversity Hospital MaastrichtBX MaastrichtThe Netherlands

Personalised recommendations